ANEB
Income statement / Annual
Last year (2024), Anebulo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Anebulo Pharmaceuticals, Inc.'s net income was -$8.20 M.
See Anebulo Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.55 M
|
$5.60 M
|
$2.96 M
|
$2.27 M
|
$150.00 K
|
| General & Administrative Expenses |
$4.76 M
|
$6.18 M
|
$3.87 M
|
$1.34 M
|
$140.11 K
|
| Selling & Marketing Expenses |
$4.80 K
|
$0.00
|
$0.00
|
$0.00
|
$23.21 K
|
| Selling, General & Administrative Expenses |
$4.76 M
|
$6.18 M
|
$3.87 M
|
$1.34 M
|
$23.35 K
|
| Other Expenses |
$0.00
|
-$41.15 K
|
-$1.78 K
|
-$1.34 K
|
$0.00
|
| Operating Expenses |
$8.31 M
|
$11.78 M
|
$6.83 M
|
$3.61 M
|
$173.35 K
|
| Cost And Expenses |
$8.31 M
|
$11.78 M
|
$6.83 M
|
$3.61 M
|
$173.35 K
|
| Interest Income |
$249.02 K
|
$92.41 K
|
$7.33 K
|
$1.02 K
|
$0.00
|
| Interest Expense |
$151.23 K
|
$0.00
|
$7.33 K
|
$11.77 K
|
$1.29 K
|
| Depreciation & Amortization |
$258.28 K
|
$11.78 M
|
$6.83 M
|
$0.00
|
$1.04 M
|
| EBITDA |
-$8.05 M |
-$11.78 M |
$5.56 K |
-$30.24 M |
-$173.35 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$107.05 K
|
$51.26 K
|
$5.56 K
|
-$26.64 M
|
-$1.29 K
|
| Income Before Tax |
-$8.20 M
|
-$11.73 M
|
-$6.83 M
|
-$30.25 M
|
-$174.64 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$104.00 K
|
-$12.89 K
|
$10.75 K
|
-$1.04 K
|
| Net Income |
-$8.20 M
|
-$11.73 M
|
-$6.83 M
|
-$30.25 M
|
-$174.64 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.32 |
-0.47 |
-0.29 |
-1.3 |
-0.0074 |
| EPS Diluted |
-0.32 |
-0.47 |
-0.29 |
-1.3 |
-0.0074 |
| Weighted Average Shares Out |
$25.82 M
|
$25.07 M
|
$23.35 M
|
$23.35 M
|
$23.72 M
|
| Weighted Average Shares Out Diluted |
$25.82 M
|
$25.07 M
|
$23.35 M
|
$23.35 M
|
$23.72 M
|
| Link |
|
|
|
|
|
